After FDA nod, Artivion moves to buy Endospan for $135M

Artivion Exercises Option to Acquire Endospan

May 8, 2026—Artivion, Inc., headquartered in suburban Atlanta, Georgia, will acquire Israel-based Endospan, a developer of solutions for the endovascular repair of aortic arch disease. In a press release reporting the company’s Q1 2026 financial results, Pat Mackin, who is Chairman, President, and Chief Executive Officer of Artivion, announced that Artivion had exercised its option to acquire Endospan for an upfront purchase price of $135 millio…

After FDA nod, Artivion moves to buy Endospan for $135M

Adjusted EBITDA rose 26% to $22.1M and net income reached $1.4M. Why it matters: NEXUS sales stay negligible in 2026 before a planned Jan. 1, 2027 launch.